ChihHui Lin - Synmosa Biopharma GM, Chairman

All Insiders . Taiwan . 
Stock . Synmosa Biopharma . Stakeholders . Insider . ChihHui Lin
4114 Stock  TWD 34.30  0.25  0.73%   

Insider

ChihHui Lin is GM, Chairman of Synmosa Biopharma
Age 40
Phone886 2 8797 7100
Webhttps://www.synmosa.com.tw

Synmosa Biopharma Management Efficiency

The company has return on total asset (ROA) of 0.0223 % which means that it generated a profit of $0.0223 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0894 %, meaning that it generated $0.0894 on every $100 dollars invested by stockholders. Synmosa Biopharma's management efficiency ratios could be used to measure how well Synmosa Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.
Synmosa Biopharma has accumulated 2.27 B in total debt with debt to equity ratio (D/E) of 0.5, which is about average as compared to similar companies. Synmosa Biopharma has a current ratio of 1.82, which is within standard range for the sector. Debt can assist Synmosa Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, Synmosa Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Synmosa Biopharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Synmosa to invest in growth at high rates of return. When we think about Synmosa Biopharma's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 7 records

INSIDER Age

Jiansheng HuangLIWANLI Innovation Co
N/A
Wenyuan ZhangLIWANLI Innovation Co
N/A
CongYuan KoLIWANLI Innovation Co
N/A
Jianxing DingLIWANLI Innovation Co
N/A
Zhiqing GaoLIWANLI Innovation Co
N/A
Congyuan KeLIWANLI Innovation Co
N/A
Shizhe LuoLIWANLI Innovation Co
N/A
Synmosa Biopharma Corporation, a specialty pharmaceutical company, researches and develops, manufactures, markets, and distributes pharmaceutical and healthcare products under the Synmosa brand name in Taiwan. The company was incorporated in 1980 and is based in Taipei, Taiwan. SYNMOSA BIOPHARMA operates under Drug ManufacturersSpecialty Generic classification in Taiwan and is traded on Taiwan OTC Exchange. Synmosa Biopharma (4114) is traded on Taiwan OTC Exchange in Taiwan and employs 16 people.

Management Performance

Return On Equity0.0894
Return On Asset0.0223

Synmosa Biopharma Leadership Team

Elected by the shareholders, the Synmosa Biopharma's board of directors comprises two types of representatives: Synmosa Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Synmosa. The board's role is to monitor Synmosa Biopharma's management team and ensure that shareholders' interests are well served. Synmosa Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Synmosa Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
ChihHui Lin, GM, Chairman
Zen Young, Marketing HP
Hongqin Bai, Sr Officer
Banson Lin, Sr Distributors
Shengren Yang, Director
JiaXin Zhang, VP
HungChin Pai, VP Officer

Synmosa Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Synmosa Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity0.0894
Return On Asset0.0223
Profit Margin0.18 %
Operating Margin0.09 %
Current Valuation17.93 B
Shares Outstanding327.14 M
Shares Owned By Insiders25.42 %
Shares Owned By Institutions0.90 %
Price To Earning14.65 X
Price To Book3.09 X

Pair Trading with Synmosa Biopharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Synmosa Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Synmosa Biopharma will appreciate offsetting losses from the drop in the long position's value.

Moving together with Synmosa Stock

  0.856620 Handa PharmaceuticalsPairCorr

Moving against Synmosa Stock

  0.852881A Fubon Financial HoldingPairCorr
  0.822891 CTBC Financial HoldingPairCorr
  0.82891B CTBC Financial HoldingPairCorr
  0.782882B Cathay Financial HoldingPairCorr
  0.714123 Center LaboratoriesPairCorr
The ability to find closely correlated positions to Synmosa Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Synmosa Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Synmosa Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Synmosa Biopharma to buy it.
The correlation of Synmosa Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Synmosa Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Synmosa Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Synmosa Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Synmosa Stock Analysis

When running Synmosa Biopharma's price analysis, check to measure Synmosa Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Synmosa Biopharma is operating at the current time. Most of Synmosa Biopharma's value examination focuses on studying past and present price action to predict the probability of Synmosa Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Synmosa Biopharma's price. Additionally, you may evaluate how the addition of Synmosa Biopharma to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY